Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers

25 Aug 2024

Abstract excerpt

Resistance to the current Androgen Receptor Signaling Inhibitor (ARSI) therapies has led to higher incidences of therapy-induced neuroendocrine-like prostate cancer (t-NEPC). This highly aggressive subtype with predominant small-cell-like characteristics is resistant to taxane chemotherapies and has a dismal overall survival. t-NEPCs are mostly treated with platinum-based drugs with a combination of etoposide or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39183332
DOI: 10.1038/s41419-024-06916-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancersPMID 39183332Read ↗

Understanding the role of Pax5 in development of taxane-resistant neuroendocrine like prostate cancersSemantic proximity Read ↗

PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.Semantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancerSemantic proximity Read ↗

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targetsSemantic proximity Read ↗

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read ↗

Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptorsSemantic proximity Read ↗

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.Semantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Semantic proximity Read ↗

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.